Try our Advanced Search for more refined results

Hemispherx Says FDA Will Accept Ampligen Analyses

By Keith Goldberg (July 11, 2012, 7:56 PM EDT) -- Hemispherx Biopharma Inc. said Wednesday that regulators will accept and review new analyses of data from a Phase III clinical trial of its chronic fatigue syndrome drug Ampligen, which could relieve the drugmaker from conducting an additional study originally requested by regulators in 2009....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!